SCHEMBL30786117

SCHEMBL30786117

NC(=O)c1ccc(F)cc1S

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.47
CES1 P23141 3/20 0.47
DGAT1 O75907 1/20 0.46
PARP1 P09874 1/20 0.44
KEAP1 Q14145 1/20 0.42
IKBKB O14920 2/20 0.38
MEN1 O00255 1/20 0.38
JAK2 O60674 1/20 0.38
EIF2AK2 P19525 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
MAPK8 P45983 2/20 0.37
KCNN4 O15554 2/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
CHUK O15111 1/20 0.36
CDC7 O00311 1/20 0.36
PRKD3 O94806 1/20 0.36
MAPK9 P45984 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30786120 0.83 KEAP1 (0.47) CES2CES1DGAT1PARP1KEAP1
SCHEMBL23732608 0.83 KEAP1 (0.47) CES2CES1DGAT1PARP1KEAP1
SCHEMBL2949444 0.81 KEAP1 (0.53) CES2CES1KEAP1MEN1KMT2A
SCHEMBL29463969 0.80 CES2 (0.52) CES2CES1DGAT1PARP1KEAP1
Rubidium SCHEMBL38662946 0.79 KEAP1 (0.52) CES2CES1KEAP1MEN1KMT2A
SCHEMBL293958 0.78 CES2 (0.68) CES2CES1DGAT1PARP1KEAP1
SCHEMBL29758181 0.78 CES2 (0.68) CES2CES1DGAT1PARP1KEAP1
SCHEMBL38662887 0.78 CES2 (0.45) CES2CES1PARP1KEAP1TDP1
SCHEMBL1436288 0.77 MAPT (0.50) CES2CES1DGAT1PARP1KEAP1
SCHEMBL148542 0.77 KEAP1 (0.53) CES2CES1DGAT1PARP1KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
CN-119604488-A Protein tyrosine kinase inhibitor and medical application thereof 苏州必扬医药科技有限公司 2025-03-11 CN disclosed
WO-2024032584-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 CES2 3920/4885CES1 1928/4885DGAT1 3415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.